vs

Side-by-side financial comparison of CorMedix Inc. (CRMD) and MERCANTILE BANK CORP (MBWM). Click either name above to swap in a different company.

CorMedix Inc. is the larger business by last-quarter revenue ($128.6M vs $67.6M, roughly 1.9× MERCANTILE BANK CORP).

CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.

Tamilnad Mercantile Bank Limited (TMB) is an Indian bank headquartered at Thoothukudi, Tamil Nadu. TMB was founded in 1921 as the Nadar Bank, but changed its name to Tamilnad Mercantile Bank in November 1962 to widen its appeal beyond the Nadar community. The bank currently has 600 full branches throughout India, 12 regional offices and two link offices, two central processing centres, one service branch, four currency chests, 48 eLobby centres, 262 cash recycler machines and 1151 automated ...

CRMD vs MBWM — Head-to-Head

Bigger by revenue
CRMD
CRMD
1.9× larger
CRMD
$128.6M
$67.6M
MBWM

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CRMD
CRMD
MBWM
MBWM
Revenue
$128.6M
$67.6M
Net Profit
$22.7M
Gross Margin
83.4%
Operating Margin
46.0%
Net Margin
33.6%
Revenue YoY
Net Profit YoY
16.1%
EPS (diluted)
$0.20
$1.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRMD
CRMD
MBWM
MBWM
Q1 26
$67.6M
Q4 25
$128.6M
$62.1M
Q3 25
$104.3M
$62.4M
Q2 25
$39.7M
$60.9M
Q1 25
$39.1M
$57.3M
Q4 24
$58.5M
Q3 24
$58.0M
Q2 24
$56.8M
Net Profit
CRMD
CRMD
MBWM
MBWM
Q1 26
$22.7M
Q4 25
$22.8M
Q3 25
$108.6M
$23.8M
Q2 25
$19.8M
$22.6M
Q1 25
$20.6M
$19.5M
Q4 24
$19.6M
Q3 24
$19.6M
Q2 24
$18.8M
Gross Margin
CRMD
CRMD
MBWM
MBWM
Q1 26
Q4 25
83.4%
Q3 25
89.3%
Q2 25
95.3%
Q1 25
95.9%
Q4 24
Q3 24
Q2 24
Operating Margin
CRMD
CRMD
MBWM
MBWM
Q1 26
Q4 25
46.0%
42.0%
Q3 25
49.2%
44.0%
Q2 25
49.2%
42.6%
Q1 25
51.5%
42.0%
Q4 24
39.7%
Q3 24
42.4%
Q2 24
41.4%
Net Margin
CRMD
CRMD
MBWM
MBWM
Q1 26
33.6%
Q4 25
36.8%
Q3 25
104.1%
38.1%
Q2 25
49.9%
37.1%
Q1 25
52.8%
34.1%
Q4 24
33.5%
Q3 24
33.8%
Q2 24
33.1%
EPS (diluted)
CRMD
CRMD
MBWM
MBWM
Q1 26
$1.32
Q4 25
$0.20
$1.41
Q3 25
$1.26
$1.46
Q2 25
$0.28
$1.39
Q1 25
$0.30
$1.21
Q4 24
$1.20
Q3 24
$1.22
Q2 24
$1.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRMD
CRMD
MBWM
MBWM
Cash + ST InvestmentsLiquidity on hand
$148.5M
Total DebtLower is stronger
$1.5M
Stockholders' EquityBook value
$405.3M
$736.9M
Total Assets
$826.1M
$6.9B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRMD
CRMD
MBWM
MBWM
Q1 26
Q4 25
$148.5M
Q3 25
$55.7M
Q2 25
$190.7M
Q1 25
$77.5M
Q4 24
Q3 24
Q2 24
Total Debt
CRMD
CRMD
MBWM
MBWM
Q1 26
$1.5M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
CRMD
CRMD
MBWM
MBWM
Q1 26
$736.9M
Q4 25
$405.3M
$724.9M
Q3 25
$374.1M
$657.6M
Q2 25
$220.6M
$631.5M
Q1 25
$114.9M
$608.3M
Q4 24
$584.5M
Q3 24
$583.3M
Q2 24
$551.2M
Total Assets
CRMD
CRMD
MBWM
MBWM
Q1 26
$6.9B
Q4 25
$826.1M
$6.8B
Q3 25
$750.9M
$6.3B
Q2 25
$252.6M
$6.2B
Q1 25
$149.6M
$6.1B
Q4 24
$6.1B
Q3 24
$5.9B
Q2 24
$5.6B
Debt / Equity
CRMD
CRMD
MBWM
MBWM
Q1 26
0.00×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRMD
CRMD
MBWM
MBWM
Operating Cash FlowLast quarter
$94.5M
Free Cash FlowOCF − Capex
$92.7M
FCF MarginFCF / Revenue
72.1%
Capex IntensityCapex / Revenue
1.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$172.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRMD
CRMD
MBWM
MBWM
Q1 26
Q4 25
$94.5M
$18.0M
Q3 25
$30.9M
$23.1M
Q2 25
$30.0M
$-7.8M
Q1 25
$19.7M
$-3.0M
Q4 24
$101.1M
Q3 24
$-8.1M
Q2 24
$9.1M
Free Cash Flow
CRMD
CRMD
MBWM
MBWM
Q1 26
Q4 25
$92.7M
Q3 25
$30.4M
Q2 25
$30.0M
Q1 25
$19.7M
Q4 24
Q3 24
Q2 24
FCF Margin
CRMD
CRMD
MBWM
MBWM
Q1 26
Q4 25
72.1%
Q3 25
29.1%
Q2 25
75.4%
Q1 25
50.5%
Q4 24
Q3 24
Q2 24
Capex Intensity
CRMD
CRMD
MBWM
MBWM
Q1 26
Q4 25
1.3%
Q3 25
0.5%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
Q3 24
Q2 24
Cash Conversion
CRMD
CRMD
MBWM
MBWM
Q1 26
Q4 25
0.79×
Q3 25
0.28×
0.97×
Q2 25
1.51×
-0.35×
Q1 25
0.96×
-0.15×
Q4 24
5.15×
Q3 24
-0.41×
Q2 24
0.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRMD
CRMD

Acquisition Of Melinta$52.9M41%
Melinta Portfolio$45.5M35%
Other$18.6M14%
Contract Revenue$7.4M6%
BARDA Agreement$4.2M3%

MBWM
MBWM

Net Interest Income$55.9M83%
Noninterest Income$11.7M17%

Related Comparisons